Cargando…

Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis

CD20 depletion is a risk factor for unfavorable outcomes of COVID-19 in people with MS (pwMS). Evidence suggests that protective IgG response to mRNA-based vaccines in B cell-depleted individuals is limited. We studied the seroconversion after the third mRNA SARS-CoV-2 vaccine in B cell-depleted pwM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Achtnichts, Lutz, Jakopp, Barbara, Oberle, Michael, Nedeltchev, Krassen, Fux, Christoph Andreas, Sellner, Johann, Findling, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707582/ https://www.ncbi.nlm.nih.gov/pubmed/34960216 http://dx.doi.org/10.3390/vaccines9121470

Ejemplares similares

SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot
por: Achtnichts, Lutz, et al.
Publicado: (2022)

Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
por: Diem, Lara, et al.
Publicado: (2018)

A comparison of balance control during stance and gait in patients with inflammatory and non-inflammatory polyneuropathy
por: Findling, Oliver, et al.
Publicado: (2018)

Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS)
por: Achtnichts, Lutz, et al.
Publicado: (2023)

T cells as the hoped-for savior for SARS-CoV-2 vaccination during CD20-depleting antibody therapy?: Commentary for: “Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.”
por: Bsteh, Gabriel, et al.
Publicado: (2021)

SARS-CoV-2 vaccination in multiple sclerosis: A clearer picture for the time point during CD20 depleting therapy
por: Schulte, Eva C., et al.
Publicado: (2021)

An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis: Immunotherapy with rituximab, ocrelizumab, and ofatumumab
por: Ovchinnikov, Arkady, et al.
Publicado: (2022)

Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies
por: Sellner, Johann, et al.
Publicado: (2021)

Cardiac Autonomic Dysfunction in Multiple Sclerosis: A Systematic Review of Current Knowledge and Impact of Immunotherapies
por: Findling, Oliver, et al.
Publicado: (2020)

The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options
por: Disanto, Giulio, et al.
Publicado: (2016)

Variables Related to Working Capability among Swiss Patients with Multiple Sclerosis—A Cohort Study
por: Findling, Oliver, et al.
Publicado: (2015)

Ocrelizumab Depletes CD20(+) T Cells in Multiple Sclerosis Patients
por: Gingele, Stefan, et al.
Publicado: (2018)

Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients
por: Bajwa, Hamza Mahmood, et al.
Publicado: (2022)

Spike-microstates correlate with interictal epileptogenic discharges: a marker for hidden epileptic activity
por: Rochas, Vincent, et al.
Publicado: (2023)

Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis()
por: Novak, Frederik, et al.
Publicado: (2021)

Multiple sclerosis at the crossroads of scientific evidence and clinical translation
por: Sellner, Johann
Publicado: (2022)

Untreated anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia progressing over 27 years
por: Schegk, E., et al.
Publicado: (2023)

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
por: Apostolidis, Sokratis A., et al.
Publicado: (2021)

Tracking Multifocal Epilepsy With Automated Electric Source Imaging in a Patient With Triple-X Syndrome
por: Gschwind, Markus, et al.
Publicado: (2022)

Evaluation of humoral and cellular response to third dose of BNT162b2 mRNA COVID-19 vaccine in patients treated with B-cell depleting therapy()
por: Firinu, Davide, et al.
Publicado: (2022)

Anti-CD20 therapy depletes activated myelin-specific CD8(+) T cells in multiple sclerosis
por: Sabatino, Joseph J., et al.
Publicado: (2019)

CD20+ B Cell Depletion in Systemic Autoimmune Diseases: Common Mechanism of Inhibition or Disease-Specific Effect on Humoral Immunity?
por: Pateinakis, Panagiotis, et al.
Publicado: (2014)

Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy
por: Sidler, Daniel, et al.
Publicado: (2022)

COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis
por: Disanto, Giulio, et al.
Publicado: (2017)

Role of Family Planning in Women With Multiple Sclerosis in Switzerland: Results of the Women With Multiple Sclerosis Patient Survey
por: Kamm, Christian P., et al.
Publicado: (2018)

Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
por: Capuano, Rocco, et al.
Publicado: (2022)

Can Systemic Anti-CD20 B Cell-Depleting Antibodies Eliminate Meningeal Follicles in Multiple Sclerosis?
por: Gupta, Sasha, et al.
Publicado: (2021)

Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data
por: Hauer, Larissa, et al.
Publicado: (2022)

Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients
por: Harberts, Aenne, et al.
Publicado: (2022)

Recognizing myorhythmia 4 months after stroke – A teaching video
por: Finkener, Sebastian, et al.
Publicado: (2022)

Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients
por: Hammer, Helly, et al.
Publicado: (2022)

Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety
por: Moser, Tobias, et al.
Publicado: (2022)

Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience
por: Perncezky, Julian, et al.
Publicado: (2022)

B cells reappear less mature and more activated after their anti-CD20–mediated depletion in multiple sclerosis
por: Nissimov, Nitzan, et al.
Publicado: (2020)

Humoral and T-Cell Mediated Response after the Third Dose of mRNA Vaccines in Patients with Systemic Lupus Erythematosus on Belimumab
por: Quartuccio, Luca, et al.
Publicado: (2023)

A R-Script for Generating Multiple Sclerosis Lesion Pattern Discrimination Plots
por: Marschallinger, Robert, et al.
Publicado: (2021)

Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study
por: Moor, Matthias B, et al.
Publicado: (2021)

A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications
por: Hauer, Larissa, et al.
Publicado: (2020)

COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma
por: Gaitzsch, Erik, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gs66saprcn0s1oei95ua6ld2rf